New business is being written on visibly better terms than the company's own recent norm, and the mix shift has just beg
The model's full reasoning — Q2 2018 call → NOWe need to determine if management indicates that the economic terms of the company's newest business have stepped up meaningfully above the company's own recent norm, and that this improvement has only begun to flow into reported results. The question is about "the company's newest business" - meaning the most recent deals, contracts, renewals, etc. The transcript discusses various aspects: Calcimimetics, Care Coordination, products, etc. But we need to see if management explicitly says that new business terms are better than recent past and that reported results still reflect old terms. Looking at the transcript: There is discussion about Calcimimetics transition, but that's about a drug transition, not necessarily about better terms. There is discussion about revenue per treatment, cost per treatment, but not about new business terms improving. There is mention of "solid organic growth" and "strong performance" but not about step-up in pricing or terms. The question specifically asks about "economic terms of the company's newest business" - like prices, rates, fees, etc. Management does not seem to indicate that they are achieving better terms on new contracts. They talk about currency headwinds, cost pressures, etc. They mention that revenue per treatment is flat to slightly down, cost per treatment flat to slightly up. That suggests no improvement in terms. Also, they mention that they expect to accelerate growth in second half, but that's about volume, not necessarily better terms. There is no mention of new contracts being signed at higher rates or better profitability. The only thing close is the divestment of Sound, but that's a one-time gain, not ongoing business terms. Thus, the answer is NO. We need to be careful: The question asks if management indicates that the terms of new business have improved and that the improvement is only beginning to flow into results. There is no such indication. Management actually says revenue per treatment is flat to slightly down, and cost per treatment flat to slightly up, which implies no improvement in economics. Therefore, answer NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| CTO | CTO Realty Growth, Inc. | Q2 2023 | 2023-07-28 | B |
| CARS | Cars.com Inc. | Q1 2023 | 2023-05-06 | B |
| BRX | Brixmor Property Group Inc. | Q1 2023 | 2023-05-02 | A |
| CRBG | Corebridge Financial, Inc. | Q4 2022 | 2023-02-22 | B |
| FLR | Fluor Corporation | Q2 2022 | 2022-08-05 | D |
| CRL | Charles River Laboratories International | Q2 2022 | 2022-08-03 | C |
| BRKL | Brookline Bancorp, Inc. | Q2 2022 | 2022-07-30 | B+ |
| INVH | Invitation Homes Inc. | Q2 2022 | 2022-07-28 | B+ |
| MTB | M&T Bank Corporation | Q2 2022 | 2022-07-20 | B+ |
| GFS | GLOBALFOUNDRIES Inc. | Q3 2021 | 2021-11-30 | A |
| GNK | Genco Shipping & Trading Limited | Q2 2021 | 2021-08-07 | A |
| ESS | Essex Property Trust, Inc. | Q2 2018 | 2018-08-03 | B+ |
| ALLY | Ally Financial Inc. | Q1 2018 | 2018-04-26 | B+ |
CRL · Q2 2022 → YESThe question is about whether management indicates that the economic terms of the company's newest business have stepped up meaningfully above the company's own recent norm, and that this improvement ...YES Management's comments on Safety Assessment pricing and backlog directly address both required elements: they describe current bookings and backlog at "escalating prices" and "meaningful price increases" that are already achieved on real transactions (not targets or future expectations), while noting that the reported Q2 results are still dominated by older 2022 terms and that the stronger pricing is accelerating into H2 and 2023 bookings.
ESS · Q2 2018 → YESThe question is about whether management indicates that the economic terms of the company's newest business have stepped up meaningfully above the company's own recent norm, and that this improvement ...YES Management describes the loss-to-lease metric rising to 3.
CTO · Q2 2023 → YESThe question is about whether management indicates that the economic terms of the company's newest business have stepped up meaningfully above the company's own recent norm, and that this improvement ...